Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Accumulated Expenses (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Other Accumulated Expenses readings, the most recent being $1.2 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 41.04% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 41.04% decrease, with the full-year FY2025 number at $1.2 million, down 41.04% from a year prior.
  • Other Accumulated Expenses hit $1.2 million in Q4 2025 for Aligos Therapeutics, down from $4.8 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $4.8 million in Q3 2025 to a low of $483000.0 in Q2 2021.
  • Median Other Accumulated Expenses over the past 5 years was $1.5 million (2022), compared with a mean of $2.0 million.
  • Biggest five-year swings in Other Accumulated Expenses: soared 639.52% in 2021 and later crashed 41.04% in 2025.
  • Aligos Therapeutics' Other Accumulated Expenses stood at $1.2 million in 2021, then increased by 19.27% to $1.5 million in 2022, then skyrocketed by 105.36% to $3.0 million in 2023, then crashed by 32.5% to $2.0 million in 2024, then crashed by 41.04% to $1.2 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $1.2 million (Q4 2025), $4.8 million (Q3 2025), and $3.8 million (Q2 2025) per Business Quant data.